Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | KCNA4 | P22459 | 1/20 | 0.34 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.34 |
| ▸ | KCNAB1 | Q14722 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13545068 | 0.83 | — | — | |
| SCHEMBL7733528 | 0.75 | KCNA4 (0.37) | ALDH1A1KCNA4KCNA1KCNAB1 | |
| SCHEMBL7643528 | 0.74 | MGAM (0.43) | ALDH1A1KCNA4KCNA1KCNAB1KDM4E | |
| SCHEMBL1970312 | 0.74 | KCNA4 (0.39) | KCNA4KCNA1KCNAB1 | |
| SCHEMBL8025488 | 0.74 | — | — | |
| SCHEMBL42141 | 0.72 | FFAR3 (0.52) | KCNA4KCNA1KCNAB1 | |
| SCHEMBL7258460 | 0.72 | KCNA4 (0.43) | KCNA4KCNA1KCNAB1 | |
| SCHEMBL1972290 | 0.71 | KCNA4 (0.32) | ALDH1A1KCNA4KCNA1KCNAB1 | |
| SCHEMBL25672287 | 0.71 | FFAR3 (0.31) | — | |
| SCHEMBL7258643 | 0.70 | KCNA4 (0.37) | KCNA4KCNA1KCNAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300937-A1 | Novel Labelled Cannabinergic Ligands and Related Analogs | MAKRIYANNIS ALEXANDROS (US) | 2021-09-30 | — | — | US | disclosed |
| WO-2019101929-A1 | HYDROGEL COMPOSITION AND ITS USES | LOEWENHIELM PETER (SE) | 2019-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300937-A1 | Novel Labelled Cannabinergic Ligands and Related Analogs | CNR1, CNR2, CHRND | ALDH1A1 3979/4885TDP1 4769/4885KCNA4 1491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.